Browsing by Author "Martínez-García, Maria"

Sort by: Order: Results:

  • Esteve-Codina, Anna; Arpí Llucià, Oriol; Martínez-García, Maria; Pineda, Estela; Mallo, Mar; Gut, Marta; Carrato, Cristina; Rovira Guerín, Ana; Lopez, Raquel; Tortosa, Avelina; Dabad, Marc; del Barco, Sonia; Heath, Simon; Bagué, Silvia; Ribalta, Teresa; Alameda Quitllet, Francisco; de la Iglesia, Nuria; Balaña, Carmen; GLIOCAT Group (Public Library of Science (PLoS), 2017)
    The molecular classification of glioblastoma (GBM) based on gene expression might better explain outcome and response to treatment than clinical factors. Whole transcriptome sequencing using next-generation sequencing ...
  • Cejalvo, Juan M.; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martínez-García, Maria; Taus García, Álvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine; Michielin, Francesca; James, Ian; Ceppi, Maurizio; Hasmann, Max; Weisser, Martin; Cervantes, Andrés (BMJ Publishing Group, 2019)
    PURPOSE:This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in ...
  • Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • Muntasell i Castellví, Aura, 1972-; Cabo, Mariona; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; López-Botet, Miguel (Frontiers, 2017)
    Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy ...
  • Balaña, Carmen; Capellades Font, Jaume; Martínez-García, Maria; Alameda Quitllet, Francisco; GLIOCAT Group (Wiley, 2017)
    We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or ...
  • Curigliano, Giuseppe; Gómez Pardo, Patricia; Meric-Bernstam, F.; Conte, Pierfranco; Lolkema, Martijn P.; Beck, Joseph Thaddeus; Bardia, Aditya; Martínez-García, Maria; Pénault-Llorca, Frédérique; Dhuria, Shyeilla; Tang, Z.; Solovieff, Nadia; Miller, Michelle; Di-Tomaso, Emmanuelle; Hurvitz, Sara A. (Elsevier, 2016)
    OBJECTIVES: Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive (HR+) breast cancer (BC). This study assessed the biological ...
  • Martínez-García, Maria; Álvarez-Linera, Juan; Carrato, Cristina; Ley, L.; Luque, Raquel; Maldonado, X.; Martínez-Aguillo, M.; Navarro, L.M.; Vaz-Salgado, M.A.; Gil-Gil, Miguel J. (SpringerOpen, 2017)
    Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for ...
  • Rodríguez Sanz, Maria, 1984-; Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Martos, Tamara; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rodriguez-Morera, Jaime; Díez Pérez, Adolfo; Albanell Mestres, Joan; Nogués Solan, Francesc Xavier (Elsevier, 2016)
    INTRODUCTION: Patients with breast cancer under aromatase inhibitor (AI) treatment often develop osteoporosis and their average bone loss rate is twice that of natural reduction during menopause, increasing fracture risk. ...